what is the new glp 1 drug Novo's Wegovy becomes first GLP-1 approved for MASH Retatrutide for weight loss: Study

Except for linagliptin, they are eliminated renally after little metabolization

This is significant because it may allow an additional reduction in liver fat, potentially helping to reduce liver inflammation and fibrosis, two causes of obesity-related complications

CV Protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis

The most serious side effects of GLP-1 receptor agonists include gallbladder problems, pancreatitis, acute kidney damage, gastroparesis, bowel obstruction, and intestinal paralysis

Ballarini, T

These findings support semaglutide 2.4 mg as an effective therapeutic option for weight and fat mass reduction while preserving, or potentially improving, muscle function and metabolic health